Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1997 Aug;56(8):481–487. doi: 10.1136/ard.56.8.481

Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide

I Martin-Suarez 1, D D'Cruz 1, M Mansoor 1, A P Fernandes 1, M Khamashta 1, G Hughes 1
PMCID: PMC1752422  PMID: 9306871

Abstract

OBJECTIVE—To review our experience with low dose intravenous pulse cyclophosphamide in the treatment of patients with severe connective tissue diseases.
PATIENTS—Ninety patients (68F:22M) with severe connective tissue diseases received a total of 883 cyclophosphamide pulses with 78 of 90 patients initially having weekly 500 mg pulses for a median of three (2-10) weeks. Diagnoses included: systemic lupus erythematosus (SLE) (n=43); systemic vasculitides (n=42); idiopathic inflammatory myopathies (n=4); mixed essential cryoglobulinaemic vasculitis (n=1). The median age was 48 (range 22-76) years with a median disease duration of 94 (18-250) months. 
RESULTS—Complete or partial remission was noted in 68 of 90 patients (75.5%) after a median follow up of 56 (5-213) months. At follow up significant median changes were noted in SLE patients: erythrocyte sedimentation rate (ESR) from 44 to 22 mm 1st hour; anti-dsDNA antibody concentrations from 81 to 48 IU/ml; proteinuria from 2.5 to 1.5 g/day; serum albumin from 36 to 40 g/l; complement C3 from 0.88 to 0.90 g/l, and C4 from 0.18 to 0.22 g/l. In the vasculitis patients significant median changes were seen in: ESR from 44 to 15 mm 1st hour; C reactive protein (CRP) from 16 to 5 g/dl; neutrophils from 8.55 to 4.3 × 109/l; platelets from 340 to 261 × 103/l, and haemoglobin from 12.6 to 13.2 g/dl. Patients with Churg-Strauss syndrome, Wegener's granulomatosis, and neuropsychiatric lupus showed the best initial response but 58% of Wegener's patients relapsed. Median corticosteroid doses were significantly reduced from 15 (5-60) mg to 10 (3-35) mg daily. Adverse events: infections (7 patients), neutropenia (5), lymphopenia (18), and haemorrhagic cystitis (1 intravenous and 2 oral cyclophosphamide), allergies to mesna (2). None of the women at risk had prolonged amenorrhoea. Five patients doubled their serum creatinine and five died from sepsis (2) or severe disease (3).
CONCLUSION—Treatment of severe connective tissue diseases with `low dose' intravenous cyclophosphamide pulses compares in efficacy with the higher monthly doses previously advocated. Treatment was well tolerated with fewer adverse effects and most significantly, there were no cases of premature ovarian failure.



Full Text

The Full Text of this article is available as a PDF (111.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Austin H. A., 3rd, Klippel J. H., Balow J. E., le Riche N. G., Steinberg A. D., Plotz P. H., Decker J. L. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986 Mar 6;314(10):614–619. doi: 10.1056/NEJM198603063141004. [DOI] [PubMed] [Google Scholar]
  2. Balow J. E., Austin H. A., 3rd, Muenz L. R., Joyce K. M., Antonovych T. T., Klippel J. H., Steinberg A. D., Plotz P. H., Decker J. L. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med. 1984 Aug 23;311(8):491–495. doi: 10.1056/NEJM198408233110802. [DOI] [PubMed] [Google Scholar]
  3. Balow J. E., Austin H. A., 3rd, Tsokos G. C., Antonovych T. T., Steinberg A. D., Klippel J. H. NIH conference. Lupus nephritis. Ann Intern Med. 1987 Jan;106(1):79–94. doi: 10.7326/0003-4819-106-1-79. [DOI] [PubMed] [Google Scholar]
  4. Belmont H. M., Storch M., Buyon J., Abramson S. New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus. 1995 Apr;4(2):104–108. doi: 10.1177/096120339500400205. [DOI] [PubMed] [Google Scholar]
  5. Bombardieri S., Hughes G. R., Neri R., Del Bravo P., Del Bono L. Cyclophosphamide in severe polymyositis. Lancet. 1989 May 20;1(8647):1138–1139. doi: 10.1016/s0140-6736(89)92416-1. [DOI] [PubMed] [Google Scholar]
  6. Boumpas D. T., Austin H. A., 3rd, Vaughan E. M., Yarboro C. H., Klippel J. H., Balow J. E. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993 Sep 1;119(5):366–369. doi: 10.7326/0003-4819-119-5-199309010-00003. [DOI] [PubMed] [Google Scholar]
  7. Boumpas D. T., Austin H. A., 3rd, Vaughn E. M., Klippel J. H., Steinberg A. D., Yarboro C. H., Balow J. E. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992 Sep 26;340(8822):741–745. doi: 10.1016/0140-6736(92)92292-n. [DOI] [PubMed] [Google Scholar]
  8. Bryant B. M., Jarman M., Ford H. T., Smith I. E. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet. 1980 Sep 27;2(8196):657–659. doi: 10.1016/s0140-6736(80)92703-8. [DOI] [PubMed] [Google Scholar]
  9. Clements P. J., Davis J. Cytotoxic drugs: their clinical application to the rheumatic diseases. Semin Arthritis Rheum. 1986 May;15(4):231–254. doi: 10.1016/0049-0172(86)90020-x. [DOI] [PubMed] [Google Scholar]
  10. Cupps T. R., Edgar L. C., Fauci A. S. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol. 1982 Jun;128(6):2453–2457. [PubMed] [Google Scholar]
  11. D'Cruz D., Payne H., Timothy A., Hughes G. R. Response of cyclophosphamide-resistant Wegener's granulomatosis to etoposide. Lancet. 1992 Aug 15;340(8816):425–426. doi: 10.1016/0140-6736(92)91505-3. [DOI] [PubMed] [Google Scholar]
  12. Fauci A. S., Haynes B. F., Katz P., Wolff S. M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983 Jan;98(1):76–85. doi: 10.7326/0003-4819-98-1-76. [DOI] [PubMed] [Google Scholar]
  13. Fauci A. S., Katz P., Haynes B. F., Wolff S. M. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med. 1979 Aug 2;301(5):235–238. doi: 10.1056/NEJM197908023010503. [DOI] [PubMed] [Google Scholar]
  14. Fauci A. S., Wolff S. M. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973 Nov;52(6):535–561. doi: 10.1097/00005792-197311000-00002. [DOI] [PubMed] [Google Scholar]
  15. Haga H. J., D'Cruz D., Asherson R., Hughes G. R. Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis. 1992 Jul;51(7):885–888. doi: 10.1136/ard.51.7.885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hoffman G. S., Kerr G. S., Leavitt R. Y., Hallahan C. W., Lebovics R. S., Travis W. D., Rottem M., Fauci A. S. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6):488–498. doi: 10.7326/0003-4819-116-6-488. [DOI] [PubMed] [Google Scholar]
  17. Hollander D., Manning R. T. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med. 1967 Aug;67(2):393–398. doi: 10.7326/0003-4819-67-2-393. [DOI] [PubMed] [Google Scholar]
  18. Houssiau F. A., D'Cruz D. P., Haga H. J., Hughes G. R. Short course of weekly low-dose intravenous pulse cyclophosphamide in the treatment of lupus nephritis: a preliminary study. Lupus. 1991 Nov;1(1):31–35. doi: 10.1177/096120339100100106. [DOI] [PubMed] [Google Scholar]
  19. Hunder G. G., Arend W. P., Bloch D. A., Calabrese L. H., Fauci A. S., Fries J. F., Leavitt R. Y., Lie J. T., Lightfoot R. W., Jr, Masi A. T. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum. 1990 Aug;33(8):1065–1067. doi: 10.1002/art.1780330802. [DOI] [PubMed] [Google Scholar]
  20. Scott D. G., Bacon P. A. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984 Mar;76(3):377–384. doi: 10.1016/0002-9343(84)90654-5. [DOI] [PubMed] [Google Scholar]
  21. Steinberg A. D., Steinberg S. C. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 1991 Aug;34(8):945–950. doi: 10.1002/art.1780340803. [DOI] [PubMed] [Google Scholar]
  22. Stillwell T. J., Benson R. C., Jr, DeRemee R. A., McDonald T. J., Weiland L. H. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum. 1988 Apr;31(4):465–470. doi: 10.1002/art.1780310402. [DOI] [PubMed] [Google Scholar]
  23. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  24. Tzioufas A. G., Manoussakis M. N., Drosos A. A., Silis G., Gharavi A. E., Moutsopoulos H. M. Enzyme immunoassays for the detection of IgG and IgM anti-dsDNA antibodies: clinical significance and specificity. Clin Exp Rheumatol. 1987 Jul-Sep;5(3):247–253. [PubMed] [Google Scholar]
  25. WALTON E. W. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J. 1958 Aug 2;2(5091):265–270. doi: 10.1136/bmj.2.5091.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Zonzits E., Aberer W., Tappeiner G. Drug eruptions from mesna. After cyclophosphamide treatment of patients with systemic lupus erythematosus and dermatomyositis. Arch Dermatol. 1992 Jan;128(1):80–82. doi: 10.1001/archderm.128.1.80. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES